Survival difference between <i>EGFR</i> Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis.
| Author | |
|---|---|
| Abstract |
:
Although superior clinical benefits of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of advanced non-small-cell lung cancer (NSCLC) had been reported, the survival difference between exon 19 deletion (Del19) and exon 21 Leu858Arg substitution (L858R) remains controversial. The purpose of this study is to investigate the differences in progression-free survival (PFS) and overall survival (OS) between different EGFR mutant subtypes among advanced NSCLC patients receiving gefitinib. |
| Year of Publication |
:
2017
|
| Journal |
:
Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
|
| Volume |
:
29
|
| Issue |
:
6
|
| Number of Pages |
:
553-560
|
| ISSN Number |
:
1000-9604
|
| URL |
:
http://dx.doi.org/10.21147/j.issn.1000-9604.2017.06.10
|
| DOI |
:
10.21147/j.issn.1000-9604.2017.06.10
|
| Short Title |
:
Chin J Cancer Res
|
| Download citation |
